ArticleTranslational lung cancer research2025
Characteristics of patients with non-small cell lung cancer and either limited or extensive synchronous metastatic spread in Germany-a population-based cancer registry cohort study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oligometastatic disease, i.e., disease with limited metastatic spread (LMS), is increasingly recognised as a distinct clinical entity as it differs from disease with extensive metastatic spread (polymetastatic disease) in terms of treatment and prognosis. This retrospective observational study aimed to characterise a population-based cohort of non-small-cell lung cancer (NSCLC) patients with synchronous metastatic disease, stratified by the extent of metastatic spread. Methods: NSCLC patients [≥18 years, diagnosed 2016-2020, ICD-10 C34, Union for International Cancer Control (UICC) stage IV at primary diagnosis] were identified from three German population-based cancer registries covering approximately 27% of the national population. The extent of metastatic disease was classified according to the 8 Results: The cohort included 8,033 NSCLC patients with distant metastasis at diagnosis of the primary tumour (1,767 with intra-thoracic LMS, 1,314 with ET-LMS, 4,196 with LMOI and 756 with EMOI). Patients with EMOI were younger (median: 64 Conclusions: We were able to identify patients with LMS in a population-based real-world dataset. This large data source forms the basis of a study series, in which subsequent analyses will assess survival prospects and optimal treatment strategies for this therapeutically relevant patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.